Insulin metabolism as well as insulin-altering therapies in Alzheimer’s disease are modulated by APOE status [37, 38], while irisin reduces diet-induced obesity and insulin resistance in vivo [28]. This evidence concerns the gene FNDC5 and early-onset autosomal dominant Alzheimer disease.